Overview

A Clinical Study to Evaluate Efficacy and Safety of HLX10 Combined With HLX04 and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC)

Status:
Not yet recruiting

Trial end date:
2025-06-30

Target enrollment:

Participant gender:

Summary

This is a two-arm, randomized, double-blinded, multicenter phase III clinical study to evaluate the clinical efficacy of HLX10 combined with HLX04 and XELOX chemotherapy versus placebo combined with Avastin® and XELOX chemotherapy in first-line treatment of patients with mCRC.

Phase:

Phase 3

Details

Lead Sponsor:

Shanghai Henlius Biotech

Treatments:

Bevacizumab